IP Library Granted Patent US 7,052,684
Granted Patent B2
US 7,052,684 · App. 10/082,221 · Granted May 30, 2006

Methods of healing wounds and fibrotic disorders using IL-10

Assignee: Renovo Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,052,684
App. No.
10/082,221
Granted
May 30, 2006
Kind
B2
Abstract

The present invention provides IL-10 or a fragment or a partially modified form thereof for use in promoting the healing of wounds and fibrotic disorders with reduced scarring and methods for same.

Claims (10)

1. A method of promoting the healing of a wound, or fibrotic disorder, with reduced scarring, the method comprising administering to a patient in need thereof an amount of an agent selected from the group consisting of:

i) human IL-10, and

ii) a partially modified form of human IL-10, that differs from human IL-10 by the addition, deletion or substitution of at least one amino acid and that has at least 95% homology with human IL-10 and that retains the anti-inflammatory healing functionality of human IL-10,

sufficient to effect said promotion with reduced scarring.

2. The method according to claim 1 , wherein the agent is administered in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.

3. The method according to claim 1 , wherein the agent is administered in conjunction with a composition for promoting the healing of wounds with reduced scarring.

4. The method according to claim 1 , wherein the agent is administered in conjunction with a composition for promoting the healing of chronic wounds.

5. The method according to claim 1 , wherein the agent is administered to a wound site or site of a fibrotic disorder.

6. The method according to claim 1 , wherein the agent is administered at a concentration of between about 1 μM and about 10 μM.

7. The method according to claim 6 , wherein the agent is administered at a concentration of between about 2.5 μM and about 5 μM.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2013
From: FERGUSON, MARK WILLIAM JAMES
To: THE VICTORIA UNIVERSITY OF MANCHESTER
Reel/Frame 031195/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2013
From: THE VICTORIA UNIVERSITY OF MANCHESTER
To: RENOVO LIMITED
Reel/Frame 031195/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2013
From: RENOVO LIMITED
To: TARGENICS INC.
Reel/Frame 031195/0532 →
CHANGE OF NAME Recorded Sep 12, 2013
From: TARGENICS INC.
To: ARMO BIOSCIENCES, INC.
Reel/Frame 031208/0898 →
Priority Claims (2)
GB 9516287 · Aug 9, 1995 · national
WO PCT/GB96/01930 · Aug 8, 1996 · international
Continuity (2)
Continuation 0901102700 · May 1, 2000
Related Publication 20020128447A1 · Sep 12, 2002